CEP78

Across TCGA pan-cancer cohorts, CEP78 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CEP78 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CEP78 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CEP78 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where CEP78 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.615	0.218	.005	30	view →
LUAD	OS	Quartile	II,III,IV	1.000	0.546	.008	22	view →
CCRCC	OS	Quartile	III,IV	0.489	0.988	.018	16	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CEP78–PDAC (OS)

Open the PDAC breakdown →